Significantly, recent insights have underscored the therapeutic promise of targeting ASNS in KRAS-mutant NSCLC, where oncogenic KRAS stimulates ASNS expression through the PI3K-AKT-NRF2-ATF4 axis [45]. Here, ATF4 is linked to non-small cell lung carcinoma.